With a midstage peek at the data on Veradermics’ oral formulation of the molecule behind the ubiquitous hair regrowth treatment Rogaine, analysts are feeling increasingly confident that the company is a cut above the rest when it comes to the opportunity in the under-tapped market for female pattern hair loss.
Source: FiercePharma
